Literature DB >> 6271671

Long-term converting enzyme inhibition and sympathetic nerve function in hypertensive humans.

M T Zanella, E L Bravo, F M Fouad, R C Tarazi.   

Abstract

Orthostatic hypotension is uncommon during oral converting enzyme inhibition, even when combined with salt depletion. To assess the mechanisms responsible for the cardiovascular homeostasis in this condition, we studied the blood pressure (BP), heart rate (HR), total plasma catecholamines (CA), and plasma renin activity (PRA) responses after 20 minutes of 60 degrees head-up tilt in four groups of hypertensive patients. Group 1 included seven untreated patients; Group 2, eight patients on converting enzyme inhibitor (captopril) therapy; Group 3, six patients on diuretic therapy and Group 4, 15 patients on combined captopril and diuretic therapy. Long-term converting enzyme inhibition alone or in combination with diuretics resulted in reduction of mean arterial pressure (MAP) associated with a marked increase in PRA and fall in plasma aldosterone concentration (PAC). Pronounced increases in HR and plasma CA on tilt were observed in all groups. In Groups 1, 2, and 3, BP was maintained during tilt; in Group 4, three patients fainted between 5 and 15 minutes while the other 12 had a normal response to tilt. Plasma catecholamines increased more significantly after 15 and 20 minutes of tilt, more in Groups 3 and 4 than in Group 1, while no differences in HR response were observed among groups. Results suggest that sympathetic compensatory mechanisms are adequate in the majority of patients to maintain BP during converting enzyme inhibition even when combined with salt depletion. In a few who exhibited orthostatic hypotension, a vasovagal attack seemed to be responsible for bradycardia and fall in BP.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271671     DOI: 10.1161/01.hyp.3.6_pt_2.ii-216

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

Review 1.  Hypertension and diabetes. Clinical problems.

Authors:  M T Zanella; R C Santiago; J R de Sá; B J Salgado; S F de Faria; R B Peres; O Kohlmann Júnior; A B Ribeiro
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.

Authors:  A A Ajayi; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

3.  Angiotensin-converting enzyme (ACE) inhibition. Therapeutic option for diabetic hypertensive patients.

Authors:  M T Zanella; B J Salgado; O Kohlmann; A B Ribeiro
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.

Authors:  D H Roberts; Y Tsao; S F Grimmer; P A Winstanley; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

5.  The effect of captopril on the reflex control heart rate: possible mechanisms.

Authors:  A A Ajayi; B C Campbell; P A Meredith; A W Kelman; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

6.  The effect of acute and chronic captopril therapy on baroreflex function in man.

Authors:  G B Kondowe; A H Deering; J G Riddell; G D Johnston; D W Harron
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.